Seres Therapeutics, Inc.
MCRB · XNASCIK 1609809fmd_1N3RTF70SV8EPT2Q4WGTAEPB6BManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 22 | 32 | 28 | 35 | 33 | 145 | 7 | 0 | 0 | 1 |
| Net interest income | 1 | 2 | – | – | – | – | – | – | – | – |
| Research and development | 82 | 89 | 96 | 80 | 91 | 142 | 110 | 118 | 65 | 49 |
| Total operating expenses | 115 | 123 | 129 | 106 | 121 | 209 | 180 | 195 | 121 | 95 |
| Operating income | (93) | (91) | (100) | (72) | (88) | (64) | (180) | (195) | (121) | (94) |
| Interest expense | – | – | – | 1 | 3 | 3 | 6 | 2 | 0 | 0 |
| Interest and investment income | – | 2 | 1 | 1 | 1 | 3 | 3 | 7 | 4 | 2 |
| Other non-operating income (expense) | 1 | 2 | 1 | 2 | (1) | (1) | (4) | 5 | (4) | 100 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | (184) | (190) | (126) | 6 |
| Net income | (92) | (89) | (99) | (70) | (89) | (66) | (250) | (114) | 0 | 6 |
| Net income to common shareholders | (92) | (89) | (99) | (70) | (89) | (66) | (250) | (114) | 0 | 6 |